A few minutes of light exposure during a draw is negligible
After obtaining favorable results in the investigator-initiated Phase III trial JETALS, and following consultation with Tokushima University, Eisai submitted a new drug application for the treatment of ALS in Japan in January 2024, leading to its approval in September, 2024 and leading to the launch today
Patients should be educated to recognize warning signs that may indicate infection, allergic reaction, or other complications requiring clinical assessment
They use HPLC purity verification and mass spectrometry for identity confirmation
Please allow 3-5 days for processing & shipping following medical approval (if required)
Had a little bit of nausea but other than that, I felt great